Clinical Trial Update: A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating dosing of intravitreal bevacizumab for retinopathy of prematurity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Cairo University | Conditions: Retinopathy of Prematurity | Phase 3 | Status: COMPLETED